Understanding CBT Success for Social Anxiety and Body Dysmorphic Disorder
This study is looking into why Cognitive Behavioral Therapy (CBT) works well for some people with Social Anxiety Disorder (SAD) or Body Dysmorphic Disorder (BDD) but not for others. Researchers will provide twelve weekly sessions of individual CBT to participants with SAD or BDD. They will measure changes in self-focused attention (how much you focus on yourself), anxiety symptoms, and brain activity to understand what factors lead to successful treatment. The study aims to enroll about 160 adults, aged 18-45, including those with SAD or BDD and healthy volunteers. The goal is to identify early indicators that predict how well someone will respond to CBT.
- Study design
- This is an interventional study involving about 160 participants, including those with Social Anxiety Disorder or Body Dysmorphic Disorder and healthy volunteers. It uses an open clinical trial design for cognitive behavioral therapy.
- What's involved
- Clinical participants will be involved for 3.5 months, completing 12 CBT sessions and 4 fMRI (functional magnetic resonance imaging) scans. Control participants will complete 3 fMRI scans over 3.5 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be assessed across a span of 3.5 months, including baseline, mid-treatment, and post-treatment measurements.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Individual Factors of CBT Underlying Success
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Angela Fang, PhD · PRINCIPAL_INVESTIGATOR · University of Washington
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Trait SFA assessed by the Public Self-Consciousness Scale- Revised (SCS-R)Across the span of 3 1/2 months: Baseline (T-2weeks), Repeat Baseline (T0), Week 3, Week 6, Week 9, Post-treatment
Participants will complete the 7-item self-report Public SCS-R measure to assess trait self-focused attention.
- Functional connectivity between the Default Mode and Dorsal Attention Networks (DMN-DAN)Across the span of 3 1/2 months: Baseline (T-2weeks), Repeat Baseline (T0), Week 6, Post-treatment
Participants will complete an MRI scan comprising both task and resting state fMRI to derive a measure of intrinsic functional connectivity between DMN and DAN using general functional connectivity.
- Anxiety symptom severity, assessed by the Structured Interview Guide for Hamilton Anxiety Scale (SIGH-A) and the Generalized Anxiety Disorder (GAD-7)Across the span of 3 1/2 months: Baseline (T-2weeks), Repeat Baseline (T0), Week 3, Week 6, Week 9, Post-treatment
The SIGH-A is a 14-item clinician-rated assessment of past-week anxiety symptom severity. Scores on the SIGH-A (together with scores on the CGI-I) will be used to calculate a categorical measure of treatment response (e.g., Remitters, Partial Responders, or NonResponders). SIGH-A items will be adapted to accommodate anxiety symptoms in a transdiagnostic sample (e.g., accounting for specific disorder-relevant fears in item 3, such as fear of negative appearance evaluation in BDD). Generalized Anxiety Disorder (GAD-7) is a 7-item self-report measure of severe anxiety
- Anxiety symptom severity, assessed by the Generalized Anxiety Disorder (GAD-7)Across the span of 3 1/2 months: Baseline (T-2weeks), Repeat Baseline (T0), Week 3, Week 6, Week 9, Post-treatment
Generalized Anxiety Disorder (GAD-7) is a 7-item self-report measure of severe anxiety
- Symptom severity associated with primary disorder, assessed by self-report versions of the Liebowitz Social Anxiety Scale (LSAS SR).Across the span of 3 1/2 months: Baseline (T-2weeks), Repeat Baseline (T0), Week 3, Week 6, Week 9, Post-treatment. DSM5 Cross Cutting: Baseline (T-2weeks), Repeat Baseline (T0), Post-treatment
Total scores from the LSAS-SR will be used toward calculating a categorical measure of treatment response (e.g., Remitters, Partial Responders, or NonResponders). Scores will also be examined as a dimensional measure of symptom severity change during treatment based on the participant's primary disorder. Standardized change scores will be calculated based on the pretreatment score on the selected measure.
- Symptom severity associated with primary disorder, assessed by self-report version of the Yale-Brown Obsessive-Compulsive Scale Modified for BDD (BDD-YBOCS SR).Across the span of 3 1/2 months: BDD-YBOCS: Baseline (T-2weeks), Repeat Baseline (T0), Week 3, Week 6, Week 9, Post-treatment. DSM5 Cross Cutting: Baseline (T-2weeks), Repeat Baseline (T0), Post-treatment
Total scores from the BDD-YBOCS-SR will be used toward calculating a categorical measure of treatment response (e.g., Remitters, Partial Responders, or NonResponders). Scores will also be examined as a dimensional measure of symptom severity change during treatment based on the participant's primary disorder. Standardized change scores will be calculated based on the pretreatment score on the selected measure.
- DSM5 Cross Cutting FormAcross the span of 3 1/2 months: Baseline (T-2weeks), Repeat Baseline (T0), Week 3, Week 6, Week 9, Post-treatment. DSM5 Cross Cutting: Baseline (T-2weeks), Repeat Baseline (T0), Post-treatment
The DSM-5 Cross Cutting Measure is a 24-item self-report measure that assesses symptom related problems over the past 2 weeks.